Roluperidone

From Wikipedia, the free encyclopedia
  (Redirected from MIN-101)
Jump to navigation Jump to search
Roluperidone
MIN-101.svg
Clinical data
Synonyms MIN-101; CYR-101; MT-210
Routes of
administration
By mouth
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
Formula C22H23F2N2O2
Molar mass 366.436 g/mol
3D model (JSmol)

Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist that is under development by Minerva Neurosciences for the treatment of schizophrenia.[1][2][3][4] One of its metabolites also has some affinity for the H1 receptor.[2] As of May 2018, the drug is in phase III clinical trials.[5]

See also[edit]

References[edit]

  1. ^ Mestre, Tiago A; Zurowski, Mateusz; Fox, Susan H (2013). "5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders". Expert Opinion on Investigational Drugs. 22 (4): 411–421. doi:10.1517/13543784.2013.769957. ISSN 1354-3784. 
  2. ^ a b Ebdrup, Bjørn H; Rasmussen, Hans; Arnt, Jørn; Glenthøj, Birte (2011). "Serotonin 2A receptor antagonists for treatment of schizophrenia". Expert Opinion on Investigational Drugs. 20 (9): 1211–1223. doi:10.1517/13543784.2011.601738. ISSN 1354-3784. 
  3. ^ Köster, Luisa-Sophie; Carbon, Maren; Correll, Christoph U (2014). "Emerging drugs for schizophrenia: an update". Expert Opinion on Emerging Drugs. 19 (4): 511–531. doi:10.1517/14728214.2014.958148. ISSN 1472-8214. 
  4. ^ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595. 
  5. ^ "Roluperidone". AdisInsight.